asston pharmaceuticals reported a net profit of ₹386.52 lakh for the financial year ended March 31, 2026, with revenue from operations rising to ₹2,546.88 lakh. The company’s board approved the audited financial results for the year and half-year ended March 31, 2026, during a meeting held on May 29, 2026. The statutory auditors, M/s Panchal S K & Associates, issued an unmodified opinion on the standalone financial results.

For the year ended March 31, 2026, the company recorded a total income of ₹3,158.43 lakh, compared to ₹2,561.02 lakh in the previous year. Total expenses for the period stood at ₹2,699.09 lakh, up from ₹2,059.42 lakh in FY25. The profit before tax for the year was ₹459.35 lakh, while the tax expense totaled ₹72.83 lakh.

The half-year results for the period ended March 31, 2026, showed a revenue from operations of ₹1,005.29 lakh and a net profit of ₹48.30 lakh. In comparison, the half-year ended March 31, 2025, reported a revenue of ₹906.85 lakh and a net profit of ₹195.17 lakh. The company noted that the figures for the half-year ended March 31, 2026, and March 31, 2025, are balancing figures derived from the audited annual results and unaudited half-yearly figures.

The earnings per share (EPS) for the year ended March 31, 2026, stood at ₹4.92 on an annualised basis, down from ₹6.14 in the previous year. The paid-up equity share capital increased to ₹851.24 lakh as of March 31, 2026, from ₹627.14 lakh in the prior year. The company’s reserves and surplus also saw a significant rise, reaching ₹3,034.99 lakh compared to ₹476.47 lakh in FY25.

Financial Results for FY26

Assets and Liabilities

The company’s total assets as of March 31, 2026, stood at ₹5,164.55 lakh, a significant increase from ₹2,812.31 lakh in the previous year. Shareholders' funds grew to ₹3,886.22 lakh, driven by the increase in equity share capital and reserves. Non-current liabilities were recorded at ₹379.40 lakh, while current liabilities stood at ₹898.92 lakh.

The cash flow statement for the year ended March 31, 2026, reflected a net increase in cash and cash equivalents of ₹109.17 lakh. Cash generated from operations was negative at ₹1,017.95 lakh, primarily due to working capital changes. However, financing activities provided a net cash inflow of ₹2,117.87 lakh, largely attributed to the issue of equity share capital.

Asston Pharmaceuticals Limited has fulfilled its regulatory compliance obligations by submitting the mandatory quarterly certificate under SEBI regulations to BSE Limited. The submission relates to the quarter ended 31st March, 2026, marking the completion of Q4FY26 compliance requirements.

Regulatory Submission Details

The certificate was submitted on 14th April, 2026, by Company Secretary and Compliance Officer Rishi Upadhaya to BSE Limited's Listing and Compliance Department. The submission was made pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting of dematerialisation activities.

Certificate Preparation and Verification

The compliance certificate was prepared by Maashitla Securities Private Limited, the company's appointed Registrar and Share Transfer Agent. Maashitla Securities, a SEBI Registered Category-I RTA with registration number INR000004370, issued the certificate on 4th April, 2026, confirming compliance with regulatory requirements.

The certificate was signed by Mukul Agrawal, Authorized Signatory of Maashitla Securities Private Limited, and digitally signed by Rishi Upadhaya on behalf of Asston Pharmaceuticals Limited.

Dematerialisation Activity Report

The quarterly report reveals no dematerialisation activity during the covered period. The compliance certificate confirms that no securities certificates were processed for dematerialisation between 1st January, 2026 to 31st March, 2026.

Company Information

Asston Pharmaceuticals Limited, formerly known as Asston Pharmaceuticals Private Limited, operates from its registered office located at 4th Floor Office No A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra. The company holds CIN number U24304MH2019PLC324187 and maintains its corporate website at www.asstonpharmaceuticals.com .

The submission of this compliance certificate demonstrates the company's commitment to maintaining regulatory adherence and transparent reporting practices as required under SEBI regulations for listed entities.